Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016, Article ID 8581421, 4 pages
http://dx.doi.org/10.1155/2016/8581421
Case Report

Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer

1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
2Department of Radiation Oncology, Emory University, Atlanta, GA 30322, USA
3Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
4Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30322, USA

Received 25 January 2016; Revised 1 March 2016; Accepted 10 March 2016

Academic Editor: Marie-Christine Kyrtsonis

Copyright © 2016 Mayur D. Mody et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Marcucci, K. Mrózek, and C. D. Bloomfield, “Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics,” Current Opinion in Hematology, vol. 12, no. 1, pp. 68–75, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Larson, “Treatment of acute myeloid leukemia in older patients,” in UpToDate, R. F. Connor, Ed., UpToDate, Waltham, Mass, USA, 2015. View at Google Scholar
  3. M. Ishikawa, K. Nakayama, M. T. Rahman et al., “Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report,” European Journal of Gynaecological Oncology, vol. 35, no. 4, pp. 443–448, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. B. Travis, M. Andersson, M. Gospodarowicz et al., “Treatment-associated leukemia following testicular cancer,” Journal of the National Cancer Institute, vol. 92, no. 14, pp. 1165–1171, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. S. D. Dertinger, S. L. Avlasevich, D. K. Torous et al., “Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy,” Toxicological Sciences, vol. 140, no. 2, pp. 307–314, 2014. View at Publisher · View at Google Scholar
  6. K. Seiter, E. Srekatragadda, D. Ponce, M. Rasul, and N. Ahmed, “Temozolomide and cisplatin in relapsed/refractory acute leukemia,” Journal of Hematology and Oncology, vol. 2, article 21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. Y.-G. Lee, J.-H. Kwon, I. Kim, S. S. Yoon, J.-S. Lee, and S. Park, “Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide,” European Journal of Haematology, vol. 92, no. 6, pp. 478–484, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Jordan and M. Carmo-Fonseca, “Molecular mechanisms involved in cisplatin cytotoxicity,” Cellular and Molecular Life Sciences, vol. 57, no. 8-9, pp. 1229–1235, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Kumar and P. B. Tchounwou, “Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells,” Oncotarget, vol. 6, no. 38, pp. 40734–40746, 2015. View at Publisher · View at Google Scholar
  10. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. V. M. Gonzalez, M. A. Fuertes, C. Alonso, and J. M. Perez, “Is cisplatin-induced cell death always produced by apoptosis?” Molecular Pharmacology, vol. 59, no. 4, pp. 657–663, 2001. View at Google Scholar · View at Scopus
  12. K. E. Pestell, S. M. Hobbs, J. C. Titley, L. R. Kelland, and M. I. Walton, “Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line,” Molecular Pharmacology, vol. 57, no. 3, pp. 503–511, 2000. View at Google Scholar · View at Scopus
  13. M. Leist, B. Single, A. F. Castoldi, S. Kühnle, and P. Nicotera, “Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis,” Journal of Experimental Medicine, vol. 185, no. 8, pp. 1481–1486, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Segal-Bendirdjian and A. Jacquemin-Sablon, “Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process,” Experimental Cell Research, vol. 218, no. 1, pp. 201–212, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. R. P. Perez, “Cellular and molecular determinants of cisplatin resistance,” European Journal of Cancer, vol. 34, no. 10, pp. 1535–1542, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Shabani, K. Ashtari, B. Behnam et al., “In vitro toxicity assay of cisplatin on mouse acute lymphoblastic leukaemia and spermatogonial stem cells,” Andrologia, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Wei, K. K. To, and S. C. Au-Yeung, “Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells,” Journal of Pharmacological Sciences, vol. 129, no. 4, pp. 210–215, 2015. View at Publisher · View at Google Scholar